1
|
Gozzo L, Di Lenarda A, Mammarella F, Olimpieri PP, Cirilli A, Cuomo M, Gulizia MM, Colivicchi F, Murri G, Kunutsor SK, Gabrielli D, Trotta F. Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation. Sci Rep 2021; 11:20689. [PMID: 34667256 PMCID: PMC8526656 DOI: 10.1038/s41598-021-99818-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 09/06/2021] [Indexed: 11/09/2022] Open
Abstract
This study aims to provide real-world data about starting-dose of NOACs and dose-adjustment in patients with atrial fibrillation (AF). In fact, even if new oral anticoagulation agents (NOACs) have a predictable effect without need for regular monitoring, dose-adjustments should be performed according to the summary of product information and international guidelines. We employed the Italian Medicines Agency monitoring registries comprising data on a nationwide cohort of patients with AF treated with NOACs from 2013 to 2018. Logistic regression analysis was used to evaluate the determinants of dosage choice. During the reference period, treatment was commenced for 866,539 patients. Forty-five percent of the first prescriptions were dispensed at a reduced dose (dabigatran 60.3%, edoxaban 45.2%, apixaban 40.9%, rivaroxaban 37.4%). The prescription of reduced dose was associated with older age, renal disease, bleeding risk and the concomitant use of drugs predisposing to bleeding, but not with CHA2DS2-VASc and HAS-BLED. A relative reduction of the proportion of patients treated with low dosages was evident overtime for dabigatran and rivaroxaban; whereas prescription of low dose apixaban and edoxaban increased progressively among elderly patients. Evidence based on real-world data shows a high frequency of low dose prescriptions of NOACs in AF patients. Except for older age, renal disease, bleeding risk and the concomitant use of drugs predisposing to bleeding, other factors that may determine the choice of reduced dose could not be ascertained. There may be potential under-treatment of AF patients, but further evaluation is warranted.
Collapse
Affiliation(s)
- L Gozzo
- Agenzia Italiana del Farmaco, Rome, Italy
| | - A Di Lenarda
- Cardiovascular Center, University Hospital and Health Services of Trieste, Trieste, Italy.
| | | | | | - A Cirilli
- Agenzia Italiana del Farmaco, Rome, Italy
| | - M Cuomo
- Agenzia Italiana del Farmaco, Rome, Italy
| | - M M Gulizia
- National Reference and High Specialization Hospital "Garibaldi-Nesima" of Catania, Catania, Italy.,Cardiology Division, San Filippo Neri Hospital, Rome, Italy.,Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.,Cardiology Division, Hospital "Murri", Fermo, Italy.,Heart Care Foundation, Florence, Italy
| | - F Colivicchi
- Cardiology Division, San Filippo Neri Hospital, Rome, Italy
| | - G Murri
- Agenzia Italiana del Farmaco, Rome, Italy
| | - S K Kunutsor
- Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - D Gabrielli
- Cardiology Division, Hospital "Murri", Fermo, Italy
| | - F Trotta
- Agenzia Italiana del Farmaco, Rome, Italy
| |
Collapse
|
2
|
Olimpieri P, Di Lenarda A, Mammarella F, Gozzo L, Cirilli A, Cuomo M, Gulizia M, Colivicchi F, Murri G, Gabrielli D, Trotta F. Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries. Int J Cardiol Heart Vasc 2020; 26:100465. [PMID: 32021902 PMCID: PMC6994529 DOI: 10.1016/j.ijcha.2019.100465] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 12/12/2019] [Accepted: 12/25/2019] [Indexed: 12/20/2022]
Abstract
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia associated with an increased risk of stroke and thromboembolism. Anticoagulation with Vitamin K antagonists (VKAs) or with novel oral anti-coagulants (NOACs) represents the cornerstone of the pharmacological treatment to reduce the risk of thromboembolism. This study aims to provide real-world data from a whole large European country about NOAC use in "non-valvular atrial fibrillation" (NVAF). Methods We analysed the Italian Medicines Agency (AIFA) monitoring registries collecting data of a nationwide cohort of patients with "NVAF" treated with NOACs. Using logistic regression analysis, baseline characteristics and treatment discontinuation information were compared among initiators of the 4 NOACs. Results In the reference period, the NOAC database collected data for 683,172 patients. The median age was 78 years with 19.5% aged 85 or older. Overall, the treatments were in accordance with guidelines. About 1/3 of patients switched from a prior VKA treatment; in the 72.3% of cases, these patients had a labile International Normalized Ratio (INR) at first prescription. The most prescribed NOAC was rivaroxaban, followed by apixaban, dabigatran and edoxaban. Conclusions This study is the largest European real-world study ever published on NOACs. It includes all Italian patients treated with NOACs since 2013 accounting for about 1/3 of subjects with AF. The enrolled population consisted of very elderly patients, at high risk of ischemic adverse events. The AIFA registries are consolidated tools that guarantee the appropriateness of prescription and provide important information for the governance of National Health System by collecting real-world data.
Collapse
Affiliation(s)
| | - A. Di Lenarda
- Cardiovascular Center, University Hospital and Health Services of Trieste, Italy
- Corresponding authors.
| | - F. Mammarella
- Agenzia Italiana del Farmaco, Rome, Italy
- Corresponding authors.
| | - L. Gozzo
- Agenzia Italiana del Farmaco, Rome, Italy
| | - A. Cirilli
- Agenzia Italiana del Farmaco, Rome, Italy
| | - M. Cuomo
- Agenzia Italiana del Farmaco, Rome, Italy
| | - M.M. Gulizia
- Cardiology Division, High Specialization Hospital “Garibaldi” of Catania, Italy
| | - F. Colivicchi
- Cardiology Division San Filippo Neri Hospital, ASL ROMA 1, Rome, Italy
| | - G. Murri
- Cardiology Division San Filippo Neri Hospital, ASL ROMA 1, Rome, Italy
| | - D. Gabrielli
- Cardiology Division, Hospital “Murri”, Fermo, Italy
| | - F. Trotta
- Agenzia Italiana del Farmaco, Rome, Italy
| |
Collapse
|
3
|
Franconi R, Massa S, Illiano E, Muller A, Cirilli A, Accardd L, Bonito PDI, Giorgi C, Venuti A. Exploiting the Plant Secretory Pathway to Improve the Anticancer Activity of a Plant-Derived HPV16 E7 Vaccine. Int J Immunopathol Pharmacol 2018. [DOI: 10.1177/205873920601900119] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
The human papillomavirus 16 (HPV16) E7 oncoprotein can be considered a ‘tumor-specific antigen’ and, therefore, it represents a promising target for a therapeutic vaccine against HPV-associated tumors. Efficient production of E7 protein with a plant-based transient expression system has been already described and it was demonstrated that E7-containing crude plant extracts confer partial protection against tumor challenge in a mouse model system. Before adopting the plant-based system as a cost-effective method for the production of an E7-based anti-cancer vaccine, some aspects, such as the oncoprotein yield, need further investigation. In the present study, we report the transient expression, mediated by a potato virus X (PVX)-derived vector, of the E7 protein targeted to the secretory system of Nicotiana benthamiana plants by using a plant-derived signal sequence. Targeting the antigen to the secretory pathway enhanced the E7 protein expression levels about five-fold. Mice immunized by s.c. administration with crude foliar extracts containing E7 showed strong stimulation of cell-mediated immune response after five boosters, as detected by ELISPOT. After challenging with the E7-expressing C3 tumor cells, tumor growth was completely inhibited in 80% of the vaccinated animals and a drastic reduction of tumor burden was observed in the remaining tumor-affected mice. These data demonstrate that, by enhancing E7 yield, it is possible to improve the anti-cancer activity of the plant-based experimental vaccine and open the way for a large-scale production of the E7 protein which could be purified or used as ‘in planta’ formulation, also suitable for oral therapeutic vaccination.
Collapse
Affiliation(s)
- R. Franconi
- ENEA, Italian National Agency for New Technologies, Energy and the Environment, BIOTEC, Laboratory of Plant Genetics and Genomics, C.R. Casaccia, P.O. Box 2400 I-00100 Roma, Italy
| | - S. Massa
- ENEA, Italian National Agency for New Technologies, Energy and the Environment, BIOTEC, Laboratory of Plant Genetics and Genomics, C.R. Casaccia, P.O. Box 2400 I-00100 Roma, Italy
| | - E. Illiano
- ENEA, Italian National Agency for New Technologies, Energy and the Environment, BIOTEC, Laboratory of Plant Genetics and Genomics, C.R. Casaccia, P.O. Box 2400 I-00100 Roma, Italy
| | - A. Muller
- Laboratory of Virology, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, Roma, Italy
| | - A. Cirilli
- Laboratory of Virology, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, Roma, Italy
| | - L. Accardd
- Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy
| | - P. DI Bonito
- Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy
| | - C. Giorgi
- Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy
| | - A. Venuti
- Laboratory of Virology, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, Roma, Italy
| |
Collapse
|
4
|
Barata I, O'Donnell B, Houdek L, Cirilli A, Haines C, Prokofieva A, Bramante R, Modayil V, Ward M, Sama A. 293 Correlation of Inferior Vena Cava/Aorta Ratio to Fluid Therapy in Clinically Dehydrated Children. Ann Emerg Med 2011. [DOI: 10.1016/j.annemergmed.2011.06.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Spencer R, Barata I, Cirilli A, Tenner K, Elkins K, Gottesman B, Ward M, Sama A. 73 Correlation between Inferior Vena Cava/Aorta Ratio and Clinical Dehydration Status in Children. Ann Emerg Med 2011. [DOI: 10.1016/j.annemergmed.2011.06.099] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Franconi R, Massa S, Illiano E, Mullar A, Cirilli A, Accardi L, Di Bonito P, Giorgi C, Venuti A. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. Int J Immunopathol Pharmacol 2006; 19:187-97. [PMID: 16569357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023] Open
Abstract
The human papillomavirus 16 (HPV16) E7 oncoprotein can be considered a "tumor-specific antigen", and therefore it represents a promising target for a therapeutic vaccine against HPV-associated tumors. Efficient production of E7 protein with a plant-based transient expression system has been already described and it was demonstrated that E7-containing crude plant extracts confer partial protection against tumor challenge in a mouse model system. Before adopting the plant-based system as a cost-effective method for the production of an E7-based anti-cancer vaccine, some aspects, such as the oncoprotein yield, need further investigation. In the present study, we report the transient expression, mediated by a potato virus X (PVX)-derived vector, of the E7 protein targeted to the secretory system of Nicotiana benthamiana plants by using a plant-derived signal sequence. Targeting the antigen to the secretory pathway enhanced the E7 protein expression levels about five-fold. Mice immunized by s.c. administration with crude foliar extracts containing E7 showed strong stimulation of cell-mediated immune response after five boosters, as detected by ELISPOT. After challenging with the E7-expressing C3 tumor cells, tumor growth was completely inhibited in 80% of the vaccinated animals and a drastic reduction of tumor burden was observed in the remaining tumor-affected mice. These data demonstrate that, by enhancing E7 yield, it is possible to improve the anti-cancer activity of the plant-based experimental vaccine and open the way for a large-scale production of the E7 protein which could be purified or used as in planta formulation, also suitable for oral therapeutic vaccination.
Collapse
Affiliation(s)
- R Franconi
- ENEA, Italian National Agency for New Technologies, Energy and the Environment, BIOTEC-GEN, I-00100 Rome, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
De Leo G, Punzo C, Bellapianta M, Cirilli A, Fato L, Valerio P, Berardi T. [Bilateral carcinoma of the breast. Our experience]. Minerva Med 1989; 80:901-5. [PMID: 2797491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- G De Leo
- Università degli Studi di Bari, Istituto di Semeiotica Chirurgica
| | | | | | | | | | | | | |
Collapse
|
8
|
Cirilli A, Valerio P, Polizzi RA, Balena V, Punzo C, De Leo G, Fato L, Berardi T. [Colorectal carcinoma in the elderly. Our experience]. Minerva Med 1989; 80:705-7. [PMID: 2779825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- A Cirilli
- Università degli Studi di Bari, Istituto di Semeiotica Chirurgica
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Fato L, Balena V, Valerio P, Marino G, Polizzi RA, De Leo G, Cirilli A, Berardi T. [The single thyroid nodule. Diagnostic and therapeutic implications]. Minerva Med 1989; 80:749-52. [PMID: 2674776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- L Fato
- Istituto di Semeiotica Chirurgica, Università degli Studi di Bari
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Oliva V, Berardi T, Punzo C, Giardina C, De Leo G, Cirilli A. [Prognostic and therapeutic implications of axillary metastases in breast cancer]. MINERVA CHIR 1986; 41:425-30. [PMID: 3725071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|